Swedbank AB Decreases Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Swedbank AB lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 69.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 728,278 shares of the company's stock after selling 1,626,793 shares during the period. Swedbank AB owned 0.58% of Henry Schein worth $50,397,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HSIC. FMR LLC grew its stake in shares of Henry Schein by 7.8% in the third quarter. FMR LLC now owns 3,280,890 shares of the company's stock worth $239,177,000 after acquiring an additional 237,888 shares during the last quarter. Southpoint Capital Advisors LP grew its position in Henry Schein by 30.0% during the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company's stock valued at $189,540,000 after purchasing an additional 600,000 shares during the last quarter. Nuance Investments LLC increased its stake in Henry Schein by 22.3% during the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company's stock valued at $166,072,000 after purchasing an additional 414,748 shares in the last quarter. Clarkston Capital Partners LLC raised its holdings in Henry Schein by 5.4% in the third quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company's stock worth $101,900,000 after buying an additional 71,560 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Henry Schein by 0.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,175,061 shares of the company's stock worth $85,662,000 after buying an additional 6,184 shares in the last quarter. Institutional investors own 96.62% of the company's stock.

Henry Schein Stock Performance

Shares of HSIC stock traded up $0.94 during mid-day trading on Thursday, reaching $80.81. 502,776 shares of the company's stock traded hands, compared to its average volume of 1,284,874. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.63. The firm has a 50 day moving average price of $73.19 and a two-hundred day moving average price of $71.27. The firm has a market capitalization of $10.08 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.04 and a beta of 0.89. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business's quarterly revenue was up .4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.32 earnings per share. On average, research analysts forecast that Henry Schein, Inc. will post 4.78 EPS for the current year.

Insiders Place Their Bets

In related news, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.14% of the company's stock.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several analyst reports. Evercore ISI raised their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an "in-line" rating in a research report on Tuesday, October 8th. Jefferies Financial Group boosted their price target on Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. StockNews.com raised Henry Schein from a "sell" rating to a "hold" rating in a report on Thursday, November 7th. Barrington Research lifted their price objective on Henry Schein from $82.00 to $90.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and upped their target price for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $80.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.